Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page 0 |8 g* X0 ^ }; A
4 R# L- j6 l4 K& w* E* h) m
( y6 Z; ^% p7 V' ?; hSub-category:" w/ f3 g3 g0 F" z3 l
Molecular Targets
2 V) m8 y0 R3 M! V7 Y+ O O8 ^& y0 |/ J8 \6 G( z; a9 [. V
, {3 |& f1 c; M( T: N% lCategory:
4 d# B9 @+ J# n- j: B+ F- z* o8 BTumor Biology 4 }: C7 i& S) D7 J" d8 X$ E% u
" k& x# D3 w" c6 I
5 x- c2 s2 v, x/ m3 {" I& @Meeting:# o' B- |( A* l% E# C
2011 ASCO Annual Meeting : c1 [6 \# h4 F# a5 A, J+ d
' K! z# S& h @- v/ g& H/ O; M! r
9 r1 ]3 {, z9 v' F+ H" r$ i5 [Session Type and Session Title:
3 C N: j6 E: `Poster Discussion Session, Tumor Biology 7 \5 k- L" W" q8 _' V7 ?
' _" E5 o4 f+ `9 d; F" V# W: t1 _. h2 U. ]/ X* x! s
Abstract No:
$ k1 v h3 y' B( x8 J1 [10517 , ?! f# Q9 e M8 C# ?% ~
; s/ }3 B @& U9 \' {" O; ^
, E$ e0 t! w3 y }8 A# q4 v% OCitation:: j$ s8 m+ d4 q4 O: E1 e
J Clin Oncol 29: 2011 (suppl; abstr 10517)
" X1 v2 b& O5 N! K( I/ N" C" a! D3 q* L8 A8 S1 g8 N; F
% y1 u1 h: n5 f$ U% o8 B& BAuthor(s):
" X1 m* T7 e) {/ wJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China . c& c6 `8 U6 j5 d/ |: L
/ |5 }- j' `2 S9 ^) p: c- @
7 j, w8 p1 l ~5 D7 Q+ ~+ H
e; T( x& A! Z w- U& r* Y0 y
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings., _. q4 \, T. {
" E/ w& k3 H. e) p* eAbstract Disclosures
3 u. S7 D$ t' t0 B' J8 E: j1 J: B4 l% l; R' ^6 a% V# p5 v' {
Abstract:
2 H7 b1 p9 J1 g& w9 e7 d* i
J2 \! _( c# a5 p0 Q% x) {# [0 H; Z/ V% U
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
. R9 Y3 G& {( ~' J% C/ L+ I
& h9 t! ?3 P/ Y2 L4 K
+ @' P; N3 n8 K9 R6 K) v |
显身卡
